FDA Grants Fast Track Designation for Torque's First Deep-Primed T Cell Cancer Immunotherapy Program, TRQ-1501

CAMBRIDGE, Mass., June 18, 2019 -- (Healthcare Sales & Marketing Network) -- Torque, a clinical-stage immuno-oncology company developing Deep-Primed T Cell Therapeutics to direct immune power deep within the tumor microenvironment, announced today that t... Biopharmaceuticals, Oncology, FDA Torque, Deep Primed T Cell, tumor microenvironment, immunotherapy

https://salesandmarketingnetwork.com/news_release_bs.html?ID=2045120

Source: HSMN NewsFeed - June 18, 2019 Category: Pharmaceuticals Source Type: news